Trials / Completed
CompletedNCT02232776
Efficacy and Safety of Losartan in Children With Ig A Nephropathy
A Prospective Study Evaluating the Efficacy and Safety of Losartan in Children With Immunoglobulin A Nephropathy
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 37 (actual)
- Sponsor
- Seoul National University Hospital · Academic / Other
- Sex
- All
- Age
- 24 Months – 18 Years
- Healthy volunteers
- Not accepted
Summary
The investigators hypothesize that using Losartan would help decrease proteinuria in controlling proteinuria in children with immunoglobulin A nephropathy.
Detailed description
Twenty nine patient with IgA nephropathy with proteinuria (urine protein to creatinine ratio \> 0.3 mg/mg) were included in the study. All patients had received losartan treatment for 24 weeks. Changes in blood pressure, proteinuria, renal function, and biochemical parameters were prospectively evaluated before and at 4 weeks and 24 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Losartan | Dose of Losartan : 0.7mg/kg once daily. |
Timeline
- Start date
- 2014-10-01
- Primary completion
- 2016-12-01
- Completion
- 2017-04-01
- First posted
- 2014-09-05
- Last updated
- 2018-10-10
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT02232776. Inclusion in this directory is not an endorsement.